Added to YB: 2025-05-08
Pitch date: 2025-05-07
RLAY [neutral]
Relay Therapeutics, Inc.
+172.67%
current return
Author Info
Steve Wagner provides in-depth analysis of my favorite individual companies. Sign up for the newsletter.
Company Info
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.
Market Cap
$1.1B
Pitch Price
$2.94
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.65
P/E
-3.60
EV/Sales
63.09
Sector
Biotechnology
Category
turnaround
Relay Therapeutics Q1 2025: Focused Discipline, Extended Runway Into 2029
RLAY (earnings update): Clinical-stage biotech streamlining to focus on lead PI3Kα inhibitor RLY-2608 (Phase 3 for breast cancer mid-2025, new Phase 1 vascular trial). Q1 cash $710M, runway to 2029 via 80% R&D cuts, 70 layoffs. Out-licensed FGFR2 asset; NRAS/Fabry paused. Risk: success now rides on single program.
Read full article (5 min)